The inhibition of poly(ADP-ribose) glycohydrolase (PARG) upregulated in HCC tissue in combination with anti-PD1 antibody is another novel strategy assessed in preclinical models of HCC [57]. This evidence concerns the gene PARG and hepatocellular carcinoma.